Where does Interpace Diagnostics Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Interpace Diagnostics Corporation ranks #26,586 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Interpace Diagnostics Corporation hold?

Interpace Diagnostics Corporation holds 10 US utility patents granted between 2016 and 2025, spanning 7 technology areas.

What is Interpace Diagnostics Corporation's Innovation Score?

Interpace Diagnostics Corporation has an Innovation Score of 25.3 out of 100 (17th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Interpace Diagnostics Corporation's patent grant rate increasing or decreasing?

Interpace Diagnostics Corporation's recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Interpace Diagnostics Corporation's patents?

Interpace Diagnostics Corporation's patents average 12.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Interpace Diagnostics Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Interpace Diagnostics Corporation

Q: What technology areas does Interpace Diagnostics Corporation focus on?

Interpace Diagnostics Corporation's top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 6 patents, ranking #717 of 2,502 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 10 granted patents across 7 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Interpace ranks #26,586 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 7 technology areas.

#26,586
of 49,997 US assignees by volume: 17th percentile
by Innovation Score (25.3/100): 12.8
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26586 · US Corporation #26,586 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,586/49,997
PHOTO-FINISH Intellipharmaceutics
CPC-NARROW C12Q · 7 areas
INNOV-THIN 25.3/100
CLAIMS-RICH 12.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Intellipharmaceutics Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Interpace’s 25.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (33%) Velocity 0.0 pts (0%) Breadth 9.4 pts (37%) Claim depth 7.7 pts (30%)

Qualcomm Incorporated · highest

85
Interpace Diagnostics · this assignee

25
3D Lighting… · lowest

7

What this shows Interpace's Innovation Score is 25.3/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Interpace?

Each dot is one of Interpace’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Interpace’s own 12.8 claims/patent is at or below the 16.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Interpace vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Interpace's grants concentrate

Interpace Diagnostics Corporation is a focused PatentsView assignee: 7 CPC subclasses with 60% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2016. By volume, Interpace sits between Intellipharmaceutics Corp. and Iontra Inc.

Intellipharmaceut…

10
Interacoustics A/S

10
Interface Biologi…

10
International Cen…

10
Interventional Sp…

10
Intrinsic Value

10
Invectys

10
Iontra

10
Interpace Diagnos… ◀

10

What this shows Interpace holds 10 patents at rank #26,602, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Interpace

By rank, the assignees closest to #26,602 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Interpace's primary technology class.

Interpace's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Interpace Diagnostics Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	10.0%
2017	1	10.0%
2018	2	20.0%
2019	2	20.0%
2020	1	10.0%
2021	2	20.0%
2025partial year	1	10.0%

Which technologies does Interpace Diagnostics Corporation patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

A61B - DIAGNOSIS; SURGERY; Identification 3

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 3

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Interpace Diagnostics Corporation's patent record in context - here's where to go next.

Interpace Diagnostics Corporation's lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 60% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #26,586 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Interpace Diagnostics Corporation against Intellipharmaceutics Corp., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.